APA

Grindedal E. M., Aarset H., Bjørnevoll I., Røyset E., Mæhle L., Stormorken A., Heramb C., Medvik H., Møller P. & Sjursen W. (20140505). The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry. : Hereditary cancer in clinical practice.

Chicago

Grindedal Eli Marie, Aarset Harald, Bjørnevoll Inga, Røyset Elin, Mæhle Lovise, Stormorken Astrid, Heramb Cecilie, Medvik Heidi, Møller Pål and Sjursen Wenche. 20140505. The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry. : Hereditary cancer in clinical practice.

Harvard

Grindedal E. M., Aarset H., Bjørnevoll I., Røyset E., Mæhle L., Stormorken A., Heramb C., Medvik H., Møller P. and Sjursen W. (20140505). The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry. : Hereditary cancer in clinical practice.

MLA

Grindedal Eli Marie, Aarset Harald, Bjørnevoll Inga, Røyset Elin, Mæhle Lovise, Stormorken Astrid, Heramb Cecilie, Medvik Heidi, Møller Pål and Sjursen Wenche. The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry. : Hereditary cancer in clinical practice. 20140505.